Lead

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
Tuesday, April 2, 2024
Neutropenia, Prostate cancer, Survival, RECIST, Prostate-specific antigen, Patient, SAN, Neoplasm, MMAE, Weight loss, Publishing, Peripheral neuropathy, University, CD46, Spacecraft, Society, Safety, ASCO, Adenocarcinoma, Fatigue, ADC, PSA, FDA, Fortis, Lead, Food, Pharmaceutical industry

“We are delighted to showcase the latest encouraging clinical data from the FOR46-001 Phase 1 ADC trial,” said Deyaa Adib, M.D., Chief Medical Officer of FibroGen.

Key Points: 
  • “We are delighted to showcase the latest encouraging clinical data from the FOR46-001 Phase 1 ADC trial,” said Deyaa Adib, M.D., Chief Medical Officer of FibroGen.
  • In the dose-expansion arm of the trial, patients were treated at the 2.7 mg/kg adjusted body weight dosing (AjBW) until disease progression.
  • The completed Phase 1 trial includes a total of 56 patients from the dose-escalation and dose-expansion cohorts.
  • These findings warrant further investigation and hold promise for addressing the therapeutic needs of patients with CD46 positive prostate cancer.

DEEP GREEN Waste & Recycling Shareholder Letter Highlights Exceptional Year

Retrieved on: 
Tuesday, April 2, 2024
Letter, Growth, Asbestos, Recycling, Lead, History, Sale, Acquisition, LES, Radon, OTC, Vanderbilt University Medical Center, DEEP, Renewable energy

Saint Simons Island, GA, April 02, 2024 (GLOBE NEWSWIRE) -- DEEP GREEN Waste & Recycling Inc. (OTC: DGWR) is pleased to release the following letter to shareholders which provides details on its recent performance highlights, service offerings and growth strategy going forward.

Key Points: 
  • Saint Simons Island, GA, April 02, 2024 (GLOBE NEWSWIRE) -- DEEP GREEN Waste & Recycling Inc. (OTC: DGWR) is pleased to release the following letter to shareholders which provides details on its recent performance highlights, service offerings and growth strategy going forward.
  • I am pleased to share with you the latest developments and achievements of DEEP GREEN Waste & Recycling Inc. over the past two months.
  • This project not only represents the largest single abatement project in the history of DEEP GREEN but also demonstrates our commitment to environmental stewardship and positions our company for accelerated growth.
  • Thank you for your continued support and confidence in DEEP GREEN Waste & Recycling Inc.

ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer

Retrieved on: 
Tuesday, April 2, 2024
Clinical research, Molecular medicine, AstraZeneca, Entrepreneurship, Patient, SAN, Mayo Clinic, Research, RNA, Bachelor of Science, Lead, University, MD, Senior, Sympathetic nervous system, Biology, Therapy, Destiny, Division, CMO, Amgen, DSM-IV codes, Pharmaceutical industry

SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a clinical stage biotechnology company developing next generation RNA therapeutics, today announced the appointment of Chris Storgard, M.D., as Chief Medical Officer (CMO).

Key Points: 
  • SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a clinical stage biotechnology company developing next generation RNA therapeutics, today announced the appointment of Chris Storgard, M.D., as Chief Medical Officer (CMO).
  • As CMO, Dr. Storgard will lead Clinical Research, Clinical Operations, Biometrics, Pharmacovigilance and Medical Affairs.
  • Dr. Storgard has a BSc in biology and an MD from the University of Saskatchewan in Canada.
  • Dr. Storgard completed a fellowship in rheumatology at Scripps Clinic and Research Center in San Diego, CA.

HealthLynked Announces Fourth Quarter and Full Year 2023 Results Highlighted by 70% Reduction in Net Loss for Q4

Retrieved on: 
Tuesday, April 2, 2024
Commitment, Growth, IBN, CFO, Physician, Patient, Lead, Sale, Way, Retirement, ARI, OTCQB, Core, Health, Pharmaceutical industry

With strategic advancements and its focus on core healthcare technologies and networking capabilities, HealthLynked achieved a significant 70% reduction in net loss for the fourth quarter, highlighting a period of fiscal management and strategic positioning for future growth.

Key Points: 
  • With strategic advancements and its focus on core healthcare technologies and networking capabilities, HealthLynked achieved a significant 70% reduction in net loss for the fourth quarter, highlighting a period of fiscal management and strategic positioning for future growth.
  • Dramatic Net Loss Reduction: A significant decrease in net loss to $1.01 million in 2023 from $8.82 million in 2022 illustrates the positive impact of our strategic divestitures, operational efficiencies, and profit stabilization despite temporary staffing changes.
  • Strategic Initiatives Lead to Reduced Operating Loss: A 73% reduction in operating loss to $1.11 million in Q4 2023, demonstrating our resilience and strategic focus during a period of staffing transition.
  • George O'Leary, CFO of HealthLynked, added, "Our strategic decisions throughout 2023 have laid a solid groundwork for growth.

SHAREHOLDER ALERT: Berger Montague Reminds Innoviz Technologies Ltd. (NASDAQ: INVZ) Investors of Class Action Lawsuit Deadline

Retrieved on: 
Tuesday, April 2, 2024
Lead, THIS, Court, LP, Security (finance)

PHILADELPHIA, April 02, 2024 (GLOBE NEWSWIRE) -- A securities fraud lawsuit has been filed against Innoviz Technologies Ltd. (“Innoviz” or the “Company”) (NASDAQ: INVZ).

Key Points: 
  • PHILADELPHIA, April 02, 2024 (GLOBE NEWSWIRE) -- A securities fraud lawsuit has been filed against Innoviz Technologies Ltd. (“Innoviz” or the “Company”) (NASDAQ: INVZ).
  • ), and is filed on behalf of purchasers of Innoviz’s securities between April 21, 2021 and February 28, 2023, inclusive (the “Class Period”).
  • Investors who purchased or acquired Innoviz securities during the Class Period may, no later than May 14, 2024, seek to be appointed as a lead plaintiff representative of the class.
  • Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Element Named to Report on Business Magazine’s Fifth Annual Women Lead Here Benchmark of Executive Gender Diversity

Retrieved on: 
Tuesday, April 2, 2024
Culture, Woman, Environment, Business, Element, Mentorship, TSX, Workforce, BRG, EFN, Report, Lead, Management

TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Element Fleet Management Corp. (TSX:EFN) (“Element” or the “Company”), the largest publicly traded, pure-play automotive fleet manager in the world, is pleased to announce it has been included in the Globe and Mail’s 2024 Report on Business magazine’s annual Women Lead Here list.

Key Points: 
  • “Element's recognition in the Women Lead Here list is a milestone in the company's ongoing efforts to foster a diverse, equitable and inclusive workforce,” said J'Nai Buchanan, Director of Diversity, Equity, Inclusion, and Belonging at Element.
  • The Women Lead Here benchmark was established in 2020 by Report on Business magazine and applies a proprietary research methodology to provide an overview of the largest Canadian corporations with the highest degree of gender diversity among executive ranks.
  • Element’s commitment to advancing diversity, equity, inclusion and belonging in its workforce has yielded important progress:
    Element’s Board of Directors membership is 60 per cent women.
  • The full list of 2024 Women Lead Here honourees can be found in the here .

Kessler Topaz Meltzer & Check, LLP Notifies The Chemours Company Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit

Retrieved on: 
Tuesday, April 2, 2024
Annual report, Ethics, CC, CFO, District court, Lead, LLP, Controller, COPY, Form 10-K, Senior, Adjustment, Collection, Court, Audit committee, Cryptocurrency

RADNOR, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that today the firm has filed a securities fraud class action lawsuit against The Chemours Company ( NYSE: CC ) (“Chemours” or the “Company”) on behalf of investors who purchased or acquired Chemours common stock between February 10, 2023 and February 28, 2024, inclusive (the “Class Period”).

Key Points: 
  • RADNOR, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that today the firm has filed a securities fraud class action lawsuit against The Chemours Company ( NYSE: CC ) (“Chemours” or the “Company”) on behalf of investors who purchased or acquired Chemours common stock between February 10, 2023 and February 28, 2024, inclusive (the “Class Period”).
  • This action, captioned Taylor Jr. v. The Chemours Company, et al., Case No.
  • Important Deadline Reminder: Investors who purchased or otherwise acquired Chemours common stock during the Class Period may, no later than May 20, 2024, move the Court to serve as lead plaintiff for the class.
  • Kessler Topaz Meltzer & Check, LLP encourages Chemours investors who have suffered significant losses to contact the firm directly to acquire more information.

AssetMark Honors Financial Advisors with Community Inspiration Award

Retrieved on: 
Monday, April 1, 2024
Organization, Lead

“We are excited to honor the incredible passion and commitment of these financial advisors who go above and beyond to create a positive impact in the lives of others,” said Michael Kim, CEO and President of AssetMark.

Key Points: 
  • “We are excited to honor the incredible passion and commitment of these financial advisors who go above and beyond to create a positive impact in the lives of others,” said Michael Kim, CEO and President of AssetMark.
  • “Their dedication to their communities is inspiring and we are proud to be part of an industry so committed to giving back.”
    Award recipients were selected by a panel of senior executives at AssetMark.
  • Nominees were evaluated on their ability to inspire, lead, and motivate others, in addition to the time and effort they dedicated to their local charity.
  • All nonprofit recipients are qualified 501(c)(3) organizations.

National Study: Ballad Health, ETSU Trauma Consolidation Saves Hundreds of Lives

Retrieved on: 
Monday, April 1, 2024
Trauma center, Level 3, Learning, Survival, Incidence, Partnership, Stunning, Ballad Health, Patient, Trauma, Research, Mortality, Lead, University, Death, Health, Injury, Johnson City Medical Center, Investment, Emergency medical services, Nursing, Patient safety, ICU, ETSU, Trauma Center, Physician, Rehabilitation, Hospital

In terms of lives, the reduction in the rate of deaths equates to hundreds of lives saved due to the successful consolidation of the region’s two Level 1 trauma centers.

Key Points: 
  • In terms of lives, the reduction in the rate of deaths equates to hundreds of lives saved due to the successful consolidation of the region’s two Level 1 trauma centers.
  • It found the patients with the highest likelihood of death due to severity had significantly improved survival rates post-consolidation.
  • Assisted by national experts, the advisory group recommended consolidation of the region’s two Level 1 trauma centers into one at Johnson City Medical Center, while maintaining Level 3 trauma services at Holston Valley Medical Center and Bristol Regional Medical Center.
  • “Excellent trauma care is a team effort from every corner of our region,” said Ballad Health Chairman and CEO Alan Levine.

Rick Harris Joins Global Search Firm Riviera Partners as Partner in Its Private Equity-Backed Practice

Retrieved on: 
Monday, April 1, 2024
Private equity, Data, Knowledge, Health care, Software, Partner, Korn Ferry, Vistaprint, Engineering, Lead, Management

New York, NY, April 01, 2024 (GLOBE NEWSWIRE) -- Riviera Partners , the leading global executive search firm specializing in executive leadership placements in technology, product, and design talent, has welcomed Rick Harris to its Private Equity-backed practice as a Partner.

Key Points: 
  • New York, NY, April 01, 2024 (GLOBE NEWSWIRE) -- Riviera Partners , the leading global executive search firm specializing in executive leadership placements in technology, product, and design talent, has welcomed Rick Harris to its Private Equity-backed practice as a Partner.
  • Before joining Riviera Partners, Harris established and co-led Raines’ Global Software & Technology Officers practice, working closely with private equity, venture capital, and public CEOs to attract transformational Product & Technology leaders.
  • Harris was previously a Partner at True Search.
  • Said Harris: “Riviera is the gold standard for recruiting engineering and product leaders, with a track record that speaks for itself.